What is the initial treatment for autoimmune hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Treatment for Autoimmune Hepatitis

The first-line treatment for autoimmune hepatitis is a combination of prednisolone (or prednisone) and azathioprine, with prednisolone typically started at 0.5-1 mg/kg/day and azathioprine at 1-2 mg/kg/day. 1

Treatment Regimen Details

The European Association for the Study of the Liver recommends the following approach:

  • Initial prednisolone dose: 30-60 mg/day
  • Azathioprine: Start at 50 mg/day, then increase to maintenance dose of 1-2 mg/kg/day
  • Monitoring: Weekly liver tests and blood counts for first 4 weeks, then monthly once stable

Recommended Tapering Schedule (for a 60 kg patient)

  • Week 1: Prednisolone 60 mg/day
  • Week 2: Prednisolone 50 mg/day
  • Week 3: Prednisolone 40 mg/day + Azathioprine 50 mg/day
  • Week 4: Prednisolone 30 mg/day + Azathioprine 50 mg/day
  • Week 5: Prednisolone 25 mg/day + Azathioprine 100 mg/day
  • Week 6: Prednisolone 20 mg/day + Azathioprine 100 mg/day
  • Weeks 7-8: Prednisolone 15 mg/day + Azathioprine 100 mg/day
  • Weeks 9-10: Prednisolone 12.5 mg/day + Azathioprine 100 mg/day
  • Beyond Week 10: Prednisolone 10 mg/day + Azathioprine 100 mg/day 1

Evidence Supporting Combination Therapy

Research has consistently shown that combination therapy is superior to monotherapy:

  • Better efficacy is achieved in the induction phase using a combination of prednisone and azathioprine from the beginning of treatment 2
  • The combination regimen is preferred, especially in elderly patients, due to lower incidence of corticosteroid-related complications 3
  • Combination therapy can achieve remission in 80% of patients within 3 years, with 10-year and 20-year survival rates exceeding 80% 4

Patient Selection for Treatment

Treatment should be initiated for:

  • Patients with incapacitating symptoms (fatigue, arthralgia)
  • Those with severe laboratory abnormalities
  • Patients with bridging necrosis or multilobular necrosis on histology 1, 3

Important Considerations and Precautions

Contraindications and Special Populations

  • Avoid azathioprine in patients with severe pre-treatment cytopenia
  • Discontinue azathioprine if possible during pregnancy (FDA pregnancy category D)
  • Budesonide is contraindicated in cirrhotic patients or those with portosystemic shunts 1

Prevention of Complications

  • All patients on steroids should receive calcium (1,000-1,200 mg daily) and vitamin D (400-800 IU daily) supplementation to prevent osteoporosis
  • Consider vaccination against hepatitis A and B for susceptible patients
  • Monitor for HBV reactivation in HBsAg-negative/anti-HBc-positive patients 1

Monitoring Treatment Response

  • Monitor serum aspartate aminotransferase and gamma-globulin levels as the most useful indices during therapy 3
  • Complete biochemical remission (normalization of both serum aminotransferase and IgG levels) is the treatment goal
  • Liver biopsy is recommended before termination of immunosuppressive treatment to confirm histological resolution 1

Alternative Therapies for Special Situations

If standard therapy fails or is contraindicated, consider:

  • Mycophenolate mofetil (MMF) - preferred initial second-line agent, especially for azathioprine intolerance
  • Tacrolimus - alternative second-line agent (56% remission rate in non-responders)
  • Cyclosporine - may be considered as salvage therapy 1

Common Pitfalls to Avoid

  • Failure to recognize relapse: Relapse occurs in 50-86% of patients after drug withdrawal 3
  • Inadequate monitoring: Interface hepatitis is found in 55% of patients with normal serum AST and γ-globulin levels during therapy 1
  • Overlooking comorbidities: Assess for metabolic syndrome components before starting glucocorticoid therapy 1
  • Missing postpartum exacerbation: Monitor serum liver enzymes at 3-week intervals for at least 3 months after delivery 1

References

Guideline

Management of Liver Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of autoimmune hepatitis.

Seminars in liver disease, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.